Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IPSC
CENTURY THERAPEUTICS, INC.
NASDAQ
$2.02
▼ DOWN 9.19% (-0.20)

KEY STATISTICS

Market Cap$175.30 M
52w High$3.04
52w Low$0.43
Dividend Yield—
Frequency—
P/E-1.91
Volume629.32K
Shares Out.86.57M

COMPANY

LEADERSHIP

Brent Pfeiffenberger
CHIEF EXECUTIVE
Brent Pfeiffenberger

COMPENSATION 2026

Salary$640,625
Stock Awards$1,869,609
Incentive Plan Pay$317,109
All Other Comp.$13,998
Total$2,381,022

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 18, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
78

PRICE TARGET

Target High$2.00
Target Low$2.00
Target Median$2.00
Target Consensus$2.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$1.63M
NOV
12
THU

PRICE

$2.02 ▼ DOWN 9.19% (−$0.20)
$2.02$2.10$2.189:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.02

About Century Therapeutics, Inc.

https://www.centurytx.com ↗

Century Therapeutics, Inc. develops allogeneic cell therapies, including CAR-iNK and CAR-iT candidates, targeting various solid tumors and blood cancers like lymphoma, glioblastoma, leukemia, and multiple myeloma.

INDUSTRY

Biotechnology

A PRODUCT CENTURY THERAPEUTICS, INC. IS KNOWN FOR

CNTY-813
CNTY-813

CNTY-813, an allogeneic iPSC-derived beta islet cell therapy by Century Therapeutics, is in preclinical development aiming for an IND in 2026 to potentially serve as a functional cure for Type 1 Diabetes.

ETFS HOLDING THIS STOCK

ETFS HOLDING
57
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 4.3M
IWM
0.01% · 3.0M
OMFS
0.17% · 222.1K
AVSC
0.02% · 213.6K
FESM
0.01% · 175.7K
GSSC
0.03% · 128.8K
DFAS
0.00% · 121.8K
XRS2.DE
0.01% · 112.7K
ZPRR.DE
0.00% · 98.0K
RSSL
0.01% · 58.3K
HLTH
1.14% · 43.3K
RTWP.L
0.03% · 32.1K
URTY
0.00% · 5.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
90
TOP 12 OF 90 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
17.8M sh · $39.02M
Ra Capital Management, L.P.
17.8M sh · $40.13M
Versant Venture Management, LLC
12.2M sh · $27.5M
Deep Track Capital, LP
9.5M sh · $21.44M
Rtw Investments, LP
8.7M sh · $19.65M
Vr Adviser, LLC
8.7M sh · $19.65M
Commodore Capital LP
8.7M sh · $19.65M
Point72 Asset Management, L.P.
6.0M sh · $13.48M
Balyasny Asset Management L.P.
5.0M sh · $11.34M
Millennium Management LLC
4.7M sh · $10.55M
Boxer Capital, LLC
3.9M sh · $6.67M
Adage Capital Partners Gp, L.L.C.
3.8M sh · $8.56M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Pfeiffenberger Brent
Sale · 31.2K shares
2026-08-14
★
OFFICER: SVP FINANCE & OPERATIONS
Carr Douglas
Sale · 275 shares
2026-08-03
★
OFFICER: SEE REMARKS
Russotti Gregory
Sale · 2.6K shares
2026-06-12
★
OFFICER: SVP FINANCE & OPERATIONS
Carr Douglas
Sale · 1.7K shares
2026-06-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
MARKET PERFORM 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT Leerink Partners MARKET PERFORM

SECTORS PEERS

PEERPRICE
EQ$2.39COMPARE
OTLK$0.64COMPARE
TELO$1.14COMPARE
OSTX$1.64COMPARE
CUE$27.88COMPARE
KPTI$1.87COMPARE
GNTA$1.00COMPARE
SNTI$0.38COMPARE